References

asurgery

Амбулаторная хирургия

Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)

2712-87412782-2591

ООО «ГРУППА РЕМЕДИУМ»

asurgery-67

Research Article

АКТУАЛЬНО

TOPICAL ISSUES

Может ли амтолметил гуацил пригодиться в хирургической практике?

Can amtolmetin guacil be useful in surgical practice?

Каратеев

А. Е.

Karateev

A. E.

noemail@neicon.ru

ФГБНУ НИИР им. В.А. НасоновойРоссияNasonova Research Institute of RheumatologyRussian Federation

2017

20062017

01-21522

2017

Каратеев А.Е.

Karateev A.E.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.a-surgeon.ru/jour/article/view/67

Нестероидные противовоспалительные препараты (НПВП) - один из основных классов анальгетиков и незаменимый компонент комплексной программы обезболивания в анестезиологической, хирургической и травматологической практике. Но использование НПВП может осложняться развитием целого спектра неблагоприятных реакций со стороны желудочно-кишечного тракта (ЖКТ), сердечно-сосудистой системы и почек, а также повышать риск развития послеоперационного кровотечения. Семейство НПВП насчитывает множество препаратов, но ни один из них нельзя признать идеальным по соотношению эффективности и безопасности. Поэтому появление нового представителя этой лекарственной группы - амтолметил гуацила - вызывает большой интерес практикующих врачей. Этот препарат обладает особенностями фармакологического действия, определяющими его гастропротективный потенциал (прежде всего, за счет повышения концентрации окиси азота в слизистой оболочке), и способностью значительно снижать негативное действие на ЖКТ. Хотя амтолметил гуацил в основном применяют для купирования боли при заболеваниях суставов и позвоночника (остеоартрит, боль в спине, ревматоидный артрит и др.), он может с успехом применяться для контроля боли у хирургических пациентов.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the main classes of analgesics and indispensable component of an integrated program of pain management in anesthetic, surgical and traumatology patients. But the use of NSAIDs may be complicated by the development of a whole range of adverse reactions in the gastrointestinal tract (GIT), the cardiovascular system and kidneys and increase the risk of postoperative hemorrhage. Family of NSAIDs has a lot of drugs but none of them can be considered ideal in terms of efficacy and safety. Therefore, the development of a new representative of this drug group - amtolmetin guacil - is of great interest to practitioners. This drug has the characteristics of the pharmacological action defining its gastroprotective potential (primarily due to the increase in the concentration of nitric oxide in the mucosa), and the ability to greatly reduce the negative effects on the gastrointestinal tract. Although amtolmetin guaci is mainly used for the relief of pain in diseases of joints and spine (osteoarthritis, back pain, rheumatoid arthritis, etc.), it can be used for pain management in surgical patients.

больпослеоперационное обезболиваниеНПВПамтолметил гуацилНПВП-гастропатиякардиова-скулярные осложненияpainpostoperative analgesiaNSAIDsamtolmetin guacilNSAID-gas-tropathycardiovascular complications

References1

Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология, 2015, 1: 4-24.

Боль (практическое руководство для врачей). Под ред. Яхно Н.Н., Кукушкина М.Л., Москва, Издательство РАМН, 2012, 512 c.

ALLegri M, Clark MR, De AndrGs J, Jensen TS. Acute and chronic pain: where we are and where we have to go. Minerva Anestesiol, 2012 Feb, 78(2): 222-35. Epub 2011 Nov 18.

Schug S, Manopas A. Update on the roLe of non-opioids for postoperative pain treatment. Best Pract Res Clin Anaesthesiol, 2007, 21(1): 15-30.

Camu F. The roLe of COX-2 inhibitors in pain modulation. Drug, 2003, 63(suppL.): 1-7.

Mehta V, Johnston A, Cheung R, BeLLo A, Langford R. Intravenous parecoxib rapidLy Leads to COX-2 inhibitory concentration of vaLdecoxib in the centraL nervous system. Clin Pharmacol Ther, 2008, 83(3): 430-435.

Dembo G, Park S, Kharasch E. CentraL nervous system concentrations of cycLooxygenase-2 inhibitors in humans. Anesthesiology, 2005, 102(2): 409-415.

Bianchi M, Martucci C, Ferrario P, Franchi S, Sacerdote P. Increased Tumor Necrosis Factor- and ProstagLandin E2 Concentrations in the CerebrospinaL FLuid of Rats with Inflammatory HyperaLgesia: The Effects of AnaLgesic Drugs. Anesth Analg, 2007, 104: 949-954.

Marret E, Kurdi 0, Zufferey P, Bonnet F: Effects of nonsteroidaL antiinflammatory drugs on patient-controLLed anaLgesia morphine side effects. Anesthesiology, 2005, 102: 1249-60.

ELia N, Lysakowski C, Tramnr M. Does MuLtimodaL AnaLgesia with Acetaminophen, Non-steroidaL Antiinflammatory Drugs, or SeLective CycLooxygenase-2 Inhibitors and Patient-controLLed AnaLgesia Morphine Offer Advantages over Morphine ALone?: Meta-anaLyses of Randomized TriaLs. Anesthesiology, 2005, 103(6): 1296-1304.

LampLot J, Wagner E, Manning D. MuLtimodaL Pain Management in TotaL Knee ArthropLasty: A Prospective Randomized ControLLed TriaL. J Arthroplasty, 2013 JuL 11. pii: S0883-5403(13)00418-X. doi: 10.1016/j.arth.2013.06.005. [Epub ahead of print].

White P, Raeder J, KehLet H. KetoroLac: its roLe as part of a muL-timodaL anaLgesic regimen. Anesth Analg, 2012, 114(2): 250254.

GuideLines for the Management of Postoperative Pain after TotaL Knee ArthropLasty Korean Knee Society Korean Knee Society. Knee Surg Relat Res, 2012, 24(4): 201-207. http://dx.doi.org/10.5792/ksrr.2012.24.4.201.

Осипова Н.А., Петрова В.В., Ермолаев П.М., Береснев В.А. Нестероидные противовоспалительные препараты в лечении послеоперационной боли у онкологических больных. Фармате-ка, 2006, 6: 74-78.

Puig MM. Can we prevent acute pain becoming chronic? J Pain Palliat Care Pharmacother, 2013 Aug, 27(3): 284-5. doi: 10.3109/15360288.2013.817499. Epub 2013 Aug 2.

Werner MU, KehLet H. Characterization of persistent postoperative pain by quantitative sensory testing. Eur J Pain Suppl, 2010, 4: 203-7.

Granot M. Can we predict persistent postoperative pain by testing preoperative experimentaL pain? Curr Opin Anaesthesiol, 2009, 22: 425-30.

PisciteLLi P, IoLascon G, Innocenti M et aL. PainfuL prosthesis: approaching the patient with persistent pain foLLowing totaL hip and knee arthropLasty. Clinical Cases in Mineral and Bone Metabolism, 2013, 10(2): 97-110.

Hofmann S, SeitLinger G, Djahani O, Pietsch M. The painfuL knee after TKA: a diagnostic aLgorithm for faiLure anaLysis. Knee Surg Sports Traumatol Arthrosc, 2011, 19(9): 1442-1452.

SeiL R, Pape D. Causes of faiLure and etioLogy of painfuL primary totaL knee arthropLasty. Knee Surg Sports Traumatol Arthrosc, 2011, 19(9): 1418-1432.

WyLde V, HewLett S, Learmonth I, Dieppe P. Persistent pain after joint repLacement: prevaLence, sensory quaLities, and postoperative determinants. Pain, 2011, 152(3): 566-572.

Liu SS, Buvanendran A, RathmeLL JP et aL. A cross-sectionaL survey on prevaLence and risk factors for persistent postsurgicaL pain 1 year after totaL hip and knee repLacement. Reg Anesth Pain Med, 2012 JuL-Aug, 37(4): 415-22. doi: 10.1097/AAP.0b013e318251b688.

Bourne R, Chesworth B, Davis A et aL. Patient Satisfaction after TotaL Knee ArthropLasty. Who is Satisfied and Who is Not? Clin Orthop Relat Res, 2010, 468: 57-63.

Harirforoosh S, Asghar W, JamaLi F. Adverse Effects of NonsteroidaL Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal. Complications. J Pharm Pharm Sci, 2013, 16(5): 821-47.

Helin-Salmivaara A, Saarelainen S, Gronroos J, et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scan J Gastroenterol, 2007, 42: 923-932.

Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens, 2009, 27(4): 886-93.

Combe B, Swergold G, McLay J et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinic trial (The MEDAL study). Rheumatology, 2009, 48: 425-432.

Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety, 2013, 22: 559-570. DOI: 10.1002/pds Published online 25 April 2013 in Wiley Online Library (wileyon-linelibrary.com).

Cordrey LJ. Tolmetin sodium, a new anti-arthritis drug: double-blind and long-term studies. Journal of the American Geriatrics Society, 1976, 24(10): 440-446.

AHFS Drug Information 2007. McEvoy GK, ed. Tolmetin. Bethesda, MD: American Society of Health-System Pharmacists; 2007: 2118-2122.

Garg A, Shoeb A, Moodahadu LS et al. Amtolmetin: A Reappraisal of NSAID with Gastroprotection. Arthritis, 2016, 2016: 7103705. doi: 10.1155/2016/7103705. Epub 2016 Mar 22.

Coruzzi G, Coppelli G, Spaggiari S et al. Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible gastric nitric oxide svnthase. Dig Liver Dis, 2002, 34(6): 403-10.

Tubaro E, Belogi L, Mezzadri CM. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal antiinflammatory drug. European Journal of Pharmacology, 2000, 387: 233-244.

Morini G, Guaita E, Lazzaretti M., et al. Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs. Digestion, 2003, 68(2-3): 124-32.

Riezzo G, Chiloiro M, Montanaro S. Protective effect of amtolmetin guacyl versus placebo diclofenac and misoprostol in healthy volunteers evaluated as gastric electrical activity in alcohol-induced stomach damage. Dig Dis Sci, 2001, 46(8): 1797-804.

Biasi G, Marcolongo R. Efficacy and safety of amtolmetin guacyl in the treatment of acute osteoarthritis. Minerva Med, 2001 Oct, 92(5): 315-24.

Tavella A, Ursini G. A clinical study on the anti-inflammatory activity and gastrointestinal tolerability of amtolmetin guacyl, a new NSAID, compared with diclofenac in aged patients with osteoarticular diseases. Article in Italian. Clin Ter, 1997 Nov, 148(11): 543-8.

Marcolongo R, Frediani B, Biasi G et al. A Meta-Analysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal Anti-Inflammatory Drug, Compared with Established Agents. Clin Drug Invest, 1999, 17(2): 89-96.

Jaji_ Z, Malaise M, Nekam K et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol, 2005, 23(6): 809-18.

Гайдукова И.З., Ребров А.П., Апаркина А.В., Хондкарян Э.В. Эффективность и кардиоваскулярная безопасность амтолме-тин гуацила (Найзилата) у больных анкилозирующим спондилитом: промежуточные результаты исследования КОРОНА. Эффективная фармакотерапия. Ревматология. Травматология. Ортопедия, 2015, 3-4: 47-53.

The authors declare that there are no conflicts of interest present.